Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
ompany Maksim-LLC. . Made and sell.
Popular Articles

Spain To Pioneer The Application Of A Nanotechnology Microscope For Brain Studies
In a world first, Spain is to use a nanotechnology microscope for brain studies as part of the Blue Brain project. The initiative is CSIC researcher Javier de Felipe"s brainchild, and researchers at the Universidad Politécnica de Madrid"s School of Computing are developing a series of tools to analyse and interpret microscope data.
new payday loan lenders
One In Ten Advanced Colon Cancer Patients Worry About Prescription Drug Costs
The vast majority of advanced colon cancer patients in a clinical trial were not concerned about the cost of prescription drugs for managing chemotherapy side effects, such as infection, pain and nausea and few adopted strategies to reduce drug cost burdens after joining the clinical trial, according to a study led by researchers at Dana-Farber Cancer Institute in Boston. Although few patients reported substantial worry about drug costs, still fewer reported discussing drug cost issues with their physicians, suggesting there are opportunities for improving how physicians integrate discussions about drug costs into clinical practice.
News of the day
NOW Election Highlights Debate Over Strategy For Future Of Feminist Movement
The AP/Kansas City Star on Sunday examined how the upcoming election for the next president of the National Organization for Women has brought to the forefront a debate over how the feminist movement should define itself moving forward. NOW President Kim Gandy is stepping down after eight years in which she led the group in opposition to many of former President George W. Bush"s policies. Running to replace her are Latifa Lyles, a 33-year-old who serves as a vice president to Gandy, and Terry O"Neill, a 56-year-old who served as NOW"s vice president for membership from 2001 to 2005. Lyles, who is black, would be NOW"s youngest president while O"Neill, who is white, would be its oldest to start a term. According to the AP/Star, the election represents "both an unusual clash of generations and an opportunity for activists to confront some of the challenges facing the feminist movement." The election will be held at NOW"s conference in Indianapolis this weekend.The candidates share the goals of ensuring that women"s needs are represented in health care reform and economic recovery efforts, and they both support working to make abortion and birth control more accessible. Lyles said she contrasts with NOW"s current membership, which is mostly white and older than age 40. Lyles believes she could help give the organization a more diverse, younger image and help encourage participation from a broader range of women. "The profile of NOW is just as important as the work we do," she said, adding, "There are a lot of antiquated notions about what feminism is." Gandy, who has endorsed Lyles, said, "It"s hard to ignore the fact there"s been a generational shift in the country, and an organization that doesn"t recognize that is living in the past." She added that Lyles" "youth is not a detriment, but an advantage. ... She"ll take NOW to a different level." Jessica Valenti, a prominent younger feminist and founder of the blog Feministing, said, "This could be the moment where NOW becomes super-relevant to the feminist movement again."O"Neill said she would focus on grassroots organizing and membership recruitment. She said that "even with a friend in the White House and a lot of friends in the Congress, it"s going to take well-organized, grassroots movement to advance our agenda." O"Neill added, "I keep hearing "Terry, I want to see more activism in my community,"" adding, "The press releases, the media exposure, invitations to the White House -- these are excellent things, but they"re not enough. The grass roots are not personally engaged." Former NOW President Patricia Ireland, who supports O"Neill, said, "There is a role that requires us to take unpopular stands and push on our friends. That"s what I think [O"Neill] really gets. She"s the one I believe will be very willing to use a wide array of tactics -- not just traditional letters and e-mails, but also engage in civil disobedience, organize fasts, be at some congressman"s district office" (Crary, AP/Kansas City Star, 6/14).
Public Health

Combined Stem Cell Gene Therapy Approach Cures Human Genetic Disease In Vitro

A study led by researchers at the Salk Institute for Biological Studies, has catapulted the field of regenerative medicine significantly forward, proving in principle that a human genetic disease can be cured using a combination of gene therapy and induced pluripotent stem (iPS) cell technology. The study, published in the May 31, 2009 early online edition of Nature, is a major milestone on the path from the laboratory to the clinic. "It"s been ten years since human stem cells were first cultured in a Petri dish," says the study"s leader Juan-Carlos Izpisa Belmonte, Ph.D., a professor in the Gene Expression Laboratory and director of the Center of Regenerative Medicine in Barcelona (CMRB), Spain. "The hope in the field has always been that we"ll be able to correct a disease genetically and then make iPS cells that differentiate into the type of tissue where the disease is manifested and bring it to clinic." Although several studies have demonstrated the efficacy of the approach in mice, its feasibility in humans had not been established. The Salk study offers the first proof that this technology can work in human cells. Belmonte"s team, working with Salk colleague Inder Verma, Ph.D., a professor in the Laboratory of Genetics, and colleagues at the CMRB, and the CIEMAT in Madrid, Spain, decided to focus on Fanconi anemia (FA), a genetic disorder responsible for a series of hematological abnormalities that impair the body"s ability to fight infection, deliver oxygen, and clot blood. Caused by mutations in one of 13 Fanconi anemia (FA) genes, the disease often leads to bone marrow failure, leukemia, and other cancers. Even after receiving bone marrow transplants to correct the hematological problems, patients remain at high risk of developing cancer and other serious health conditions. After taking hair or skin cells from patients with Fanconi anemia, the investigators corrected the defective gene in the patients" cells using gene therapy techniques pioneered in Verma"s laboratory. They then successfully reprogrammed the repaired cells into induced pluripotent stem (iPS) cells using a combination of transcription factors, OCT4, SOX2, KLF4 and cMYC. The resulting FA-iPS cells were indistinguishable from human embryonic stem cells and iPS cells generated from healthy donors. Since bone marrow failure as a result of the progressive decline in the numbers of functional hematopoietic stem cells is the most prominent feature of Fanconi anemia, the researchers then tested whether patient-specific iPS cells could be used as a for transplantable hematopoietic stem cells. They found that FA-iPS cells readily differentiated into hematopoietic progenitor cells primed to differentiate into healthy blood cells. "We haven"t cured a human being, but we have cured a cell," Belmonte explains. "In theory we could transplant it into a human and cure the disease." Although hurdles still loom before that theory can become practice - in particular, preventing the reprogrammed cells from inducing tumors - in coming months Belmonte and Verma will be exploring ways to overcome that and other obstacles. In April 2009, they received a $6.6 million from the California Institute Regenerative Medicine (CIRM) to pursue research aimed at translating basic science into clinical cures. "If we can demonstrate that a combined iPS-gene therapy approach works in humans, then there is no limit to what we can do," says Verma. Researchers who also contributed to the work include first author Ángel Raya, as well as Ignasi Rodríguez-Pizà, Rita Vassena, María José Barrero, Antonella Consiglio, Eduard Sleep, Federico González, Gustavo Tiscornia, Elena Garreta, Trond Aasen, and Anna Veiga of the Center for Regenerative Medicine in Barcelona, Spain; Guillermo Guenechea, Susana Navarro, Paula Río, and Juan Bueren of the Hematopoiesis and Gene Therapy Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnolgicas in Madrid, Spain; and Maria Castellà and Jordi Surrallés of the Department of Genetics and Microbiology, Universitat Autonoma de Barcelona. Gina Kirchweger Salk Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

Copyright 2009